First use in gastric bypass at Memorial Hermann-Texas Medical Center
Johnson & Johnson MedTech, a global leader in surgical technologies and solutions, announced completion of the first cases in the clinical trial for the OTTAVA Robotic Surgical System. The cases mark the first clinical experience with the OTTAVA System.
Dr. Erik Wilson, Chief of Minimally Invasive and Elective General Surgery UT Health Houston and the lead investigator for the clinical study, performed Roux-en-Y gastric bypass surgery using the OTTAVA Robotic Surgical System at Memorial Hermann-Texas Medical Center.
“Surgical robotics is at the forefront of innovation in minimally invasive surgery,” Dr. Wilson said. “I am proud to have performed the first clinical study cases with OTTAVA and potentially help advance the standard in surgical robotics.”
OTTAVA is designed as a multi-specialty soft-tissue surgery robot, supporting a broad range of procedures across patient anatomy and surgical specialties, including the most complex surgeries that require a multi-quadrant approach.
Health Technology Insights: WEA Foundation to Expand School Mental Health Programs
Data from this investigation aims to support the system’s ability to perform a variety of procedures. Upon completion of the study, the company plans to submit the OTTAVA system for De Novo authorization in the United States, targeting an indication covering multiple procedures in general surgery within the upper abdomen, such as gastric bypass, gastric sleeve, small bowel resection and hiatal hernia repair.
“We are proud to reach this important milestone in our robotic surgery program,” said Hani Abouhalka, Company Group Chairman, Surgery, Johnson & Johnson MedTech. “OTTAVA is a key innovation in our portfolio of advanced surgical technologies – all of which are designed to transform the surgical experiences across all surgery. Our people work side-by-side with surgical teams in ORs around the world every day to raise the standard of care for patients and deliver what’s next in surgery.”
Health Technology Insights: Your Behavioral Health Appoints Matthew Zubiller as Chief Executive Officer
Johnson & Johnson MedTech’s OTTAVA system received investigational device exemption (IDE) approval from the U.S. FDA in late 2024. The system is designed to advance clinical innovation in general surgery, a stronghold for Johnson & Johnson MedTech’s broader surgery business. OTTAVA is designed to address unmet needs that persist in robotic surgery today and support complex procedures. The system’s unique unified architecture, surgical instrumentation powered by Ethicon expertise, and future connection to the Polyphonic digital ecosystem are designed to meet the needs of each patient’s care and each surgeon’s clinical approach.
“As a company operating at the intersection of biology and technology, clinical evidence generation is the core of our innovation programs to advance surgical technology for patients,” said Peter Schulam M.D., PhD, Chief Scientific Officer, Johnson & Johnson MedTech. “Through this clinical study, we are proud to be partnering with surgeons to gather evidence and support the ongoing pursuit of scientific study for the advancement of robotic-assisted minimally invasive surgery.”
Health Technology Insights: Farmacias Plaza and Alivia Launch Glow Med Labels in Puerto Rico
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
